Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation
Open Access
- 10 December 2025
- journal article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 278
Abstract
Schizophrenia (SCZ), a chronic psychiatric disorder, is characterized by cognitive impairment, hallucinations, and delusions, with current antipsychotic treatments offering limited efficacy and considerable side effects. Cannabidiol (CBD), a nonpsychoactive compound from Cannabis sativa, has shown promise in treating neurological and psychiatric conditions, though its precise mechanisms in schizophrenia remain unclear. Using network pharmacology, this study predicts CBD's targets and pathways in schizophrenia, highlighting LPS-induced neuroinflammation and implicating 5-HT1AR-MAPK signaling as one potential contributor. In vitro, CBD (10 mg/kg, i.p.) treatment significantly reduced pro-inflammatory cytokines (e.g., NO, IL-1β, IL-6, TNF-α) and modulated the 5HT1AR-MAPK pathway, including increased 5HT1AR expression and decreased MAPK/ERK1/2 phosphorylation (p < 0.05). In vivo, CBD alleviated SCZ-like symptoms in a ketamine-induced animal model, reducing anxiety in the open field (p < 0.01) and elevated plus maze tests (p < 0.01), improving spatial memory in the Y-maze (p < 0.01) and social behavior (p < 0.0001) after 5 consecutive days of treatment. Critically, we validated CBD's central anti-inflammatory effects by demonstrating reduced pro-inflammatory cytokine levels in both plasma and brain tissues (p < 0.05). Further correlation analysis established a direct link between brain cytokine suppression and behavioral improvements, integrating in vitro findings from BV2 microglial cells with in vivo neuroinflammatory and behavioral outcomes. These findings suggest the potential therapeutic benefits of CBD for SCZ, though further research, particularly clinical trials, is required to validate its efficacy and establish it as a novel therapeutic strategy.Keywords
Funding Information
- the Scientific Startup Foundation for Doctors of North Sichuan Medical College (CBY23-QDA03, CBY23-QDA11)
- the Nanchong Science and Technology Bureau (No. 22SXQT0162)
- the Famous and Senior Traditional Chinese Medicine Physicians' Medical Records Research Center (YAZX21-YB-34)
- Sichuan Provincial Natural Science Foundation (24NSFSC1730)
This publication has 110 references indexed in Scilit:
- Emerging evidence for astrocyte dysfunction in schizophreniaGlia, 2022
- The role of serotonin neurotransmission in rapid antidepressant actionsPsychopharmacology, 2022
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trialPsychopharmacology, 2018
- The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence AnalysesCurrent Protocols in Bioinformatics, 2016
- Serotonin (5‐HT) regulates neurite outgrowth through 5‐HT1A and 5‐HT7 receptors in cultured hippocampal neuronsJournal of Neuroscience Research, 2014
- An overview of the Amber biomolecular simulation packageWIREs Computational Molecular Science, 2012
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- Agonist- and antagonist-induced plasticity of rat 5-HT1A receptor in hippocampal cell cultureSynapse, 1999
- Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective DisorderArchives of General Psychiatry, 1999
- Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjectsPsychopharmacology, 1982